|
Kissei Pharmaceutical Co., Ltd. (4547.T) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Kissei Pharmaceutical Co., Ltd. (4547.T) Bundle
Gardez un aperçu de Kissei Pharmaceutical Co., Ltd. (4547T) Analyse d'évaluation en utilisant notre calculatrice sophistiquée DCF! Ce modèle Excel est préchargé avec des données précises (4547T), vous permettant d'ajuster les prévisions et les hypothèses pour déterminer la valeur intrinsèque de Kissei Pharmaceutical avec précision.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2021 |
AY2 2022 |
AY3 2023 |
AY4 2024 |
AY5 2025 |
FY1 2026 |
FY2 2027 |
FY3 2028 |
FY4 2029 |
FY5 2030 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 69,044.0 | 65,381.0 | 67,493.0 | 75,579.0 | 88,330.0 | 94,242.9 | 100,551.7 | 107,282.8 | 114,464.4 | 122,126.8 |
| Revenue Growth, % | 0 | -5.31 | 3.23 | 11.98 | 16.87 | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 |
| EBITDA | 10,647.0 | 20,261.0 | 17,808.0 | 18,720.0 | 20,250.0 | 22,710.4 | 24,230.7 | 25,852.8 | 27,583.4 | 29,429.8 |
| EBITDA, % | 15.42 | 30.99 | 26.38 | 24.77 | 22.93 | 24.1 | 24.1 | 24.1 | 24.1 | 24.1 |
| Depreciation | 3,148.0 | 3,730.0 | 4,109.0 | 4,254.0 | 4,615.0 | 5,127.9 | 5,471.2 | 5,837.4 | 6,228.2 | 6,645.1 |
| Depreciation, % | 4.56 | 5.71 | 6.09 | 5.63 | 5.22 | 5.44 | 5.44 | 5.44 | 5.44 | 5.44 |
| EBIT | 7,499.0 | 16,531.0 | 13,699.0 | 14,466.0 | 15,635.0 | 17,582.6 | 18,759.6 | 20,015.3 | 21,355.2 | 22,784.7 |
| EBIT, % | 10.86 | 25.28 | 20.3 | 19.14 | 17.7 | 18.66 | 18.66 | 18.66 | 18.66 | 18.66 |
| Total Cash | 44,454.0 | 53,152.0 | 49,599.0 | 45,933.0 | 48,654.0 | 63,147.5 | 67,374.7 | 71,884.9 | 76,697.0 | 81,831.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23,058.0 | 23,058.0 | 22,806.0 | 28,679.0 | 29,653.0 | 32,790.9 | 34,985.9 | 37,327.9 | 39,826.7 | 42,492.8 |
| Account Receivables, % | 33.4 | 35.27 | 33.79 | 37.95 | 33.57 | 34.79 | 34.79 | 34.79 | 34.79 | 34.79 |
| Inventories | 20,118.0 | 18,987.0 | 22,798.0 | 26,296.0 | 24,979.0 | 29,220.7 | 31,176.8 | 33,263.8 | 35,490.5 | 37,866.3 |
| Inventories, % | 29.14 | 29.04 | 33.78 | 34.79 | 28.28 | 31.01 | 31.01 | 31.01 | 31.01 | 31.01 |
| Accounts Payable | 7,909.0 | 4,104.0 | 4,617.0 | 4,893.0 | 4,602.0 | 6,833.9 | 7,291.4 | 7,779.5 | 8,300.2 | 8,855.9 |
| Accounts Payable, % | 11.46 | 6.28 | 6.84 | 6.47 | 5.21 | 7.25 | 7.25 | 7.25 | 7.25 | 7.25 |
| Capital Expenditure | -1,485.0 | -1,919.0 | -2,547.0 | -1,833.0 | -4,507.0 | -3,088.8 | -3,295.6 | -3,516.2 | -3,751.5 | -4,002.7 |
| Capital Expenditure, % | -2.15 | -2.94 | -3.77 | -2.43 | -5.1 | -3.28 | -3.28 | -3.28 | -3.28 | -3.28 |
| Tax Rate, % | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 |
| EBITAT | 5,301.3 | 12,939.8 | 10,542.6 | 11,173.1 | 11,980.2 | 13,355.3 | 14,249.3 | 15,203.2 | 16,220.9 | 17,306.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -28,302.7 | 12,076.8 | 9,058.6 | 4,499.1 | 12,140.2 | 10,246.7 | 12,731.3 | 13,583.5 | 14,492.8 | 15,463.0 |
| WACC, % | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 57,855.8 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 16,082 | |||||||||
| Terminal Value | 2,964,939 | |||||||||
| Present Terminal Value | 2,374,399 | |||||||||
| Enterprise Value | 2,432,254 | |||||||||
| Net Debt | -23,889 | |||||||||
| Equity Value | 2,456,143 | |||||||||
| Diluted Shares Outstanding, MM | 44 | |||||||||
| Equity Value Per Share | 56,305.32 |
What You Will Receive
- Authentic 4547T Financial Data: Pre-loaded with Kissei Pharmaceutical's historical and forecasted data for accurate analysis.
- Completely Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instantaneous Calculations: Watch as Kissei Pharmaceutical's intrinsic value updates in real time based on your modifications.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants who aim for precise DCF outcomes.
- User-Friendly Interface: Intuitive layout with straightforward instructions suitable for all skill levels.
Key Features
- 🔍 Real-Life Kissei Financials: Pre-filled historical and projected data for Kissei Pharmaceutical Co., Ltd. (4547T).
- ✏️ Fully Customizable Inputs: Tailor all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas compute Kissei’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: View Kissei’s valuation instantly after making adjustments.
- Scenario Analysis: Evaluate and compare results for various financial assumptions side-by-side.
How It Functions
- Step 1: Download the Excel spreadsheet.
- Step 2: Examine the pre-filled Kissei Pharmaceutical data (historical and projected).
- Step 3: Modify key assumptions (highlighted in yellow) according to your evaluation.
- Step 4: Observe real-time recalculations for Kissei Pharmaceutical's intrinsic value.
- Step 5: Utilize the results for investment choices or reporting purposes.
Why Choose This Calculator for Kissei Pharmaceutical Co., Ltd. (4547T)?
- Accuracy: Utilizes actual Kissei financial figures to ensure precise data.
- Flexibility: Allows users to experiment with and adjust inputs with ease.
- Time-Saving: Avoid the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for those without extensive financial modeling knowledge.
Who Should Use Kissei Pharmaceutical Co., Ltd. (4547T)?
- Individual Investors: Make informed decisions regarding the purchase or sale of Kissei Pharmaceutical stock.
- Financial Analysts: Enhance valuation practices with readily available financial models tailored for the pharmaceutical sector.
- Consultants: Provide clients with expert valuation insights on Kissei Pharmaceutical quickly and with precision.
- Business Owners: Gain an understanding of how companies like Kissei are valued to inform your own business strategies.
- Finance Students: Explore valuation methodologies using real-world data and case studies from the pharmaceutical industry.
Contents of the Template
- Pre-Filled Data: Contains Kissei Pharmaceutical’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for computing WACC with customizable inputs.
- Key Financial Ratios: Assess Kissei Pharmaceutical’s profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
- User-Friendly Dashboard: Visual charts and tables summarizing critical valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.